DOCSLIB.ORG

Saving Lives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Saving Lives Saving lives Annual report and accounts 2020 Oxford Biomedica in brief Oxford Biomedica is a leading, fully integrated, cell and gene therapy group focused on developing life changing treatments for serious diseases. Cell and gene therapy is the treatment of disease by the delivery of therapeutic DNA into a patient’s cells. This can be achieved either in vivo (referred to as gene therapy) or ex vivo (referred to as cell therapy), the latter being where the patient’s cells are genetically modified outside the body before being re-infused. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of cell and gene therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Juno Therapeutics/Bristol Myers Squibb, SIO Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long term economic interests in other potential cell and gene therapy products. 1 Saving lives 2 Questions and answers Additionally the Group has signed a three-year master supply and 8 The Group’s COVID-19 development agreement with AstraZeneca for large-scale manufacturing vaccine journey of the adenoviral based COVID-19 vaccine the (“Oxford AstraZeneca 12 Market overview COVID-19 vaccine”) Oxford Biomedica is based across several locations 15 Strategic Report in Oxfordshire, UK and employs more than 670 people. 16 Group at a glance 18 Product pipeline 20 The Group’s business model 22 The Group’s stakeholders 26 Operational highlights delivered in 2020 27 Financial highlights delivered in 2020 28 Chair’s statement 30 Chief Executive Officer’s and 2020 performance review 38 Management team 40 Delivery of 2020 objectives 41 Objectives set for 2021 42 Financial review 51 Environmental, Social and Governance Report 67 Non-financial statement 69 Corporate Governance 70 Principal risks, uncertainties and risk management 78 Board of Directors 80 Corporate Governance Report 96 Directors’ Remuneration Report 124 Directors’ Report 132 Independent auditors’ report 143 Group financial statements 144 Consolidated statement of comprehensive income 145 Statement of financial positions 146 Statements of cash flows 147 Statements of changes in equity attributable to owners of the parent 148 Notes to the consolidated financial statements 185 Other matters 185 Glossary 188 Advisers and contact details Saving lives 1 ving lives Sa We are Oxford Biomedica. A life saving healthcare company at the leading edge of cell and gene therapy medicine. Oxford Biomedica plc | Annual report and accounts 2020 2 Saving lives Questions and answers Q&A Our new Chair, Dr. Roch Doliveux, responds to the FAQs of the moment. Q: What attracted you to the role of Chair “ I am fascinated by the cell and at Oxford Biomedica? gene therapy space, which is A: I am fascinated by the cell and gene therapy space, which is poised to deliver the next wave poised to deliver the next wave of breakthroughs in medicine. of breakthroughs in medicine.” OXB has a clear leadership position in lentiviral vectors on which to build, with the potential to save and improve the lives of so many more people. Also, OXB enjoys a collegial culture both amongst the management team and the Board. This spirit of winning together is quite special and I particularly thrive in this environment. Q: What impressed you most once you joined? “ When I joined, I knew there A: When I joined, I knew there was great depth in the scientific was great depth in the scientific knowledge around lentiviral vectors at OXB. Having spent knowledge around lentiviral time with our scientists, I am now even more impressed. vectors at OXB. Having spent I am equally impressed by the Chemistry, Manufacturing and time with our scientists, I am Controls (CMC), knowhow and ability to deliver all the way now even more impressed.” through particularly competitive manufacturing: these are impressive combined strengths which differentiates OXB in the marketplace. Oxford Biomedica plc | Annual report and accounts 2020 3 ving lives Sa Q: What surprised you most once you joined? “ OXB has become one of A: The biggest surprise was what OXB has been able to achieve the main manufacturers for and deliver with the Oxford AstraZeneca COVID-19 vaccine the Oxford AstraZeneca in such a short period of time. The team promptly applied its COVID-19 vaccine in the UK expertise to work with a new viral vector, a different process with amazing performance and scaling up to levels we have not worked at before. Using and a sense of urgency.” our knowhow in technology, CMC and manufacturing, OXB has become one of the main manufacturers for the Oxford AstraZeneca COVID-19 vaccine in the UK with amazing Q&A performance and a sense of urgency. Q: How have the first 9 months in the role been? A: Busier than I thought! With the COVID-19 crisis, it has been an unusual time to join an organisation, as I have only met John Dawson, our CEO, in person. However, the culture and “ A major concern for us was collegiality of OXB, combined with frequent interactions, have made it possible to achieve a lot. As I joined, the Group achieved preventing COVID-19 in our a successful fundraise quickly followed by the decision and workplace. Thankfully, our successful implementation of the manufacturing of the manufacturing staff were Oxford AstraZeneca COVID-19 vaccine. A major concern for vaccinated in February with the us was preventing COVID-19 in our workplace. Thankfully, vaccine we are manufacturing our manufacturing staff were vaccinated in February with and the risk and worry that the vaccine we are manufacturing and the risk and worry COVID-19 could disrupt that that COVID-19 could disrupt that important work dissipated. Perhaps more importantly for the long term, the Board important work dissipated.” committed to our strategy to grow our Contract Development and Manufacturing organisation (CDMO) leadership position and build our portfolio of medicines targeting severe diseases. Q: What has your experience as CEO of UCB and in other roles, allowed you to bring to the OXB Board? A: Having been the CEO of an innovative biopharma company as well as mentoring many CEOs, there are certainly many experiences that could be relevant for OXB on the delivery of our services and new medicines. I bring to OXB my whole drive, purpose and my energy. The purpose drives the strategy and focus on implementation drives performance. I believe these involve both organic and inorganic developments and partnerships. I also trust that the connections I have built over the years will help future partnerships and therefore help enable OXB to maximise its full potential. Dr. Roch Doliveux, Chair A biography detailing Dr. Roch’s extensive experience in the sector can be found on page 78. Oxford Biomedica plc | Annual report and accounts 2020 4 Saving lives Questions and answers Q: What drives you? “ I am driven mostly by saving A: I am driven mostly by three things. Firstly saving lives and lives and making the lives of making the lives of those that are suffering better. This is those that are suffering better.” done through hard and smart work. The second dimension that drives me is talent, and maximising the potential of talent and teams. The third area is the need to perform, for example, performance in revenues, market share, profitability, IP, share price and performance in bringing life- saving medicines to patients. Q: How do you see the cell and gene therapy field in the coming years and OXB’s opportunity to capitalise on this? A: Monoclonal antibodies and other large molecules have been an amazing source of innovative medicines and have made many companies successful, including UCB. Cell and gene therapy is clearly the next wave, just like antibodies were 20 years ago; many of the same key success factors will apply, including great technology platforms, the right disease targets, performant CMC and manufacturing, solid development and regulatory skills, customer centric commercialisation, strong IP, access to knowledge, long term capital and great talent. “ Cell and gene therapy is clearly the next wave, just like antibodies were 20 years ago.” Oxford Biomedica plc | Annual report and accounts 2020 5 ving lives Sa Q: You were known for being acquisitive in your “ In such a complex and rapidly time at UCB, do you see growth being mainly organic moving world, we need or inorganic? diversity of thought, talent A: Both; however the most important part is to build on and experiences around strengths and combining strengths which could be through the Board table and within technology partnerships not just via a traditional acquisition the wider Group to help route. I am not driven by acquisitions but by continuously building strengths to maximise the potential of the company, make the right decisions.” whether it was for UCB as CEO, and now for OXB as Chair. Q: Are you committed to OXB being a CDMO as well as developing its own portfolio of medicines? A: Of course. We have a strong CDMO business and will build on this under my leadership. We are also committed to bringing our own new medicines to patients, this may also be done via partnerships as I have discussed above. Q: How important is good corporate governance for a FTSE250 company like OXB? A: Good corporate governance is a must in the same way as “ The cash generated by the good auditing of the accounts and regulatory compliance.
Load more

Recommended publications
  • Dáil Éireann
    Vol. 1003 Thursday, No. 6 28 January 2021 DÍOSPÓIREACHTAÍ PARLAIMINTE PARLIAMENTARY DEBATES DÁIL ÉIREANN TUAIRISC OIFIGIÚIL—Neamhcheartaithe (OFFICIAL REPORT—Unrevised) 28/01/2021A00100Covid-19 Vaccination Programme: Statements � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 565 28/01/2021N00100Ceisteanna ó Cheannairí - Leaders’ Questions � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 593 28/01/2021Q00500Ceisteanna ar Reachtaíocht a Gealladh - Questions on Promised Legislation � � � � � � � � � � � � � � � � � � � � � � 602 28/01/2021T01100Covid-19 (Social Protection): Statements � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 611 28/01/2021JJ00200Response of the Department of Housing, Local Government and Heritage to Covid-19: Statements � � � � � � 645 28/01/2021XX02400Ábhair Shaincheisteanna Tráthúla - Topical Issue Matters � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 683 28/01/2021XX02600Saincheisteanna Tráthúla - Topical Issue Debate � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 685 28/01/2021XX02700School Facilities � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 685 28/01/2021YY00400Post Office Network � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 687 28/01/2021AAA00150Architectural Heritage � � � � � �
    [Show full text]
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • March 2018 1 MARKET UPDATE| HEALTHCARE
    MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co.
    [Show full text]
  • British Politics and Policy at LSE: How to Mitigate the Risk of Psychological Injury to COVID-19 Frontline Workers Page 1 of 2
    British Politics and Policy at LSE: How to mitigate the risk of psychological injury to COVID-19 frontline workers Page 1 of 2 How to mitigate the risk of psychological injury to COVID-19 frontline workers Jennifer Brown and Yvonne Shell discuss the possibility of healthcare workers experiencing post-traumatic stress disorder and other similar conditions as a result of dealing with COVID-19. They write that the antidote includes clarity in chain of command, effective supplies of equipment, and good communication. A perfect storm is gathering for the experience of psychological consequences by frontline staff during this world health crisis. Essential for key workers’ mental health in the face of a disaster such as that presented by the COVID-19 pandemic is resilience. This is the lesson learnt by Doctors Without Borders – an international medical humanitarian organization – for the welfare of its staff working in disaster areas. Resilience is personal, organisational, family and community. Resilience happens in a context and is a shared experience. That’s why our ‘clap for carers’ on a Thursday evening may have such significance for frontline workers beyond the immediacy of expressed appreciation. We already know that medical staff, social and care workers as well as emergency personnel can suffer symptoms of stress in normal circumstances and may be especially vulnerable in extremis. It is widely accepted that those who undertake such roles may experience Post-Traumatic Stress Disorder (PTSD), a condition we readily associate with veterans from war. PTSD occurs when a person is confronted by actual or threatened exposure to death or serious injury to themselves or others.
    [Show full text]
  • The Incidence, Characteristics and Outcomes of Pregnant Women Hospitalized with Symptomatic And
    medRxiv preprint doi: https://doi.org/10.1101/2021.01.04.21249195; this version posted January 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . 1 The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and 2 asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: a national cohort 3 study using the UK Obstetric Surveillance System (UKOSS) 4 5 Covid-19 in pregnancy 6 7 Nicola Vousden1,2 PhD, Kathryn Bunch MA1, Edward Morris MD3, Nigel Simpson MBChB4, Christopher 8 Gale PhD5, Patrick O’Brien MBBCh6, Maria Quigley MSc1, Peter Brocklehurst MSc7 9 Jennifer J Kurinczuk MD1, Marian Knight DPhil1 10 11 1National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of 12 Oxford, UK 13 2School of Population Health & Environmental Sciences, King’s College London, UK 14 3Royal College of Obstetricians and Gynaecologists, London, UK 15 4Department of Women's and Children's Health, School of Medicine, University of Leeds, UK 16 5Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London, London, 17 UK 18 6Institute for Women’s Health, University College London, London, UK 19 7Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, UK 20 21 Corresponding author: 22 Marian Knight, National Perinatal Epidemiology Unit, Nuffield Department of Population Health, 23 University of Oxford, Old Rd Campus, Oxford, OX3 7LF, UK 24 Tel: 01865 289727 Email: [email protected] 25 26 Non-standard abbreviations: 27 Royal College of Obstetricians and Gynaecologists - RCOG 28 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Vaccinating the World in 2021
    Vaccinating the World in 2021 TAMSIN BERRY DAVID BRITTO JILLIAN INFUSINO BRIANNA MILLER DR GABRIEL SEIDMAN DANIEL SLEAT EMILY STANGER-SFEILE MAY 2021 RYAN WAIN Contents Foreword 4 Executive Summary 6 Vaccinating the World in 2021: The Plan 8 Modelling 11 The Self-Interested Act of Vaccinating the World 13 Vaccinating the World: Progress Report 17 Part 1: Optimise Available Supply in 2021 19 Part 2: Reduce Shortfall by Boosting Vaccine Supply 22 The Short Term: Continue Manufacturing Medium- and Long-Term Manufacturing Part 3: Ensure Vaccine Supply Reaches People 37 Improving Absorption Capacity: A Blueprint Reducing Vaccine Hesitancy Financing Vaccine Rollout Part 4: Coordinate Distribution of Global Vaccine Supply 44 Conclusion 47 Endnotes 48 4 Vaccinating the World in 2021 Foreword We should have recognised the warning signs that humanity’s international response to Covid-19 could get bogged down in geopolitical crosscurrents. In early March 2020, a senior Chinese leader proclaimed in a published report that Covid-19 could be turned into an opportunity to increase dependency on China and the Chinese economy. The following month, due in part to the World Health Organisation’s refusal to include Taiwan in its decision- making body, the Trump administration suspended funding to the agency. In May 2020, President Trump announced plans to formally withdraw from it. Quite naturally, many public-health experts and policymakers were discouraged by the growing possibility that global politics could overshadow efforts to unite the world in the effort to fight the disease. However, this report from the Global Health Security Consortium offers hope. It recommends a strategic approach to “vaccine diplomacy” that can help the world bring the pandemic under control.
    [Show full text]
  • RCP BIA 2020 Review January 2021 FINAL.Pdf
    UK BioIndustry Association UK Listed Biotech & Life Sciences 2020 – Year in Review– May you live in interesting times Radnor Broad UK Listed Biotech Index - 2 Year Chart Unweighted Weighted FTSE All-Share 350 300 250 200 150 100 50 Dec '20 Dec Dec '18 Dec '19 Mar '19 Jun '19 Sep '19 Dec '20 Mar '20 Jun '20 Sep Source: FactSet, Radnor 2020 has been an extraordinary year across the market but there is no doubt that the UK listed biotech sector has been in the front line in more ways than one. Investors have clearly responded to both the efforts made by the sector to combat the pandemic, but also the structural growth opportunity within biotech that the pandemic has bought into sharper focus. Not only have we seen headline share price underperformance reverse sharply through the course of 2020, but critically, the pace and scale of sector fundraising activity has stepped up materially. Perhaps most importantly, the number of investors active in the sector (institutional, private wealth, individual and overseas) have expanded. This feature alone has gone a long way towards addressing one of the key issues facing the sector. The BioIndustry Association ▪ Sector Outperformance. 2020 has been the strongest period of price is a research client of Radnor outperformance over the last 10 years. Interestingly, this outperformance has Capital Partners Ltd. been delivered across all the sub-indices making up the Broad Biotech index; although performance levels have varied somewhat. This outperformance has MiFID II – this research is also been much more pronounced then looking at the sector on an equal deemed to be a minor, non- monetary benefit.
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]
  • Oxford Biomedica Delivering Commercial Gene-Therapy Vector
    31st March 2017 Pharmaceuticals & Biotechnology Oxford BioMedica Delivering commercial gene-therapy vector OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties Source: Fidessa on commercial products developed with its LentiVector® platform: extensive IP, facilities, and know-how for production and development of lentiviral vectors to Market data generate gene-based therapies. OXB intends to out-license its five clinical EPIC/TKR OXB candidates and to continue investment in R&D. Bioprocessing royalties are likely Price (p) 5.2 to result in significant upside potential in the near future. 12m High (p) 6.5 12m Low (p) 3.0 ► Strategy: Oxford BioMedica has four strategic objectives: delivery of process Shares (m) 3,088.2 development services which embed its technology in partners’ commercial Mkt Cap (£m) 159.0 products; commercial manufacture of lentiviral vector; out-licensing of EV (£m) 178.1 proprietary candidates; and investment in R&D and the LentiVector platform. Free Float 65% Market LSE ► Revenues: Bioprocessing and process development command fees-for-service, with process development also incurring upfront, milestone and incentive Description payments plus licensing income and royalties on commercial products. Out- Oxford BioMedica is a UK-based licensed candidates will deliver licensing fees plus high royalties if successful. biopharmaceutical company specializing in cell and gene therapies developed using lentiviral vectors, ► Valuation: An EV/sales multiple of 4x prospective sales for the bioprocessing gene-delivery vehicles based on virus and process development services is readily justified, which generates a value particles.
    [Show full text]
  • Post-COVID-19 Paediatric Inflammatory Multisystem Syndrome
    Original research Arch Dis Child: first published as 10.1136/archdischild-2020-320388 on 16 March 2021. Downloaded from Post- COVID-19 paediatric inflammatory multisystem syndrome: association of ethnicity, key worker and socioeconomic status with risk and severity Jonathan Broad ,1,2 Julia Forman,3 James Brighouse,4 Adebola Sobande,5 Alysha McIntosh,1 Claire Watterson,1 Elizabeth Boot,6 Felicity Montgomery,5 Iona Gilmour,5 Joy Tan,5 Mary Johanna Fogarty,7 Xabier Gomez,6 Ronny Cheung ,5 Jon Lillie ,6 Vinay Shivamurthy,4 Jenny Handforth,1 Owen Miller ,7 PIMS- TS study group ► Additional material is ABSTRACT What is already known on this topic? published online only. To view, Objectives Patients from ethnic minority groups please visit the journal online and key workers are over- represented among adults (http:// dx. doi. org/ 10. 1136/ SARS- CoV-2 appears to be less severe and to hospitalised or dying from COVID-19. In this population- ► archdischild- 2020- 320388). lead to fewer hospital admissions in children based retrospective cohort, we describe the association For numbered affiliations see compared with adults. In the adult population, of ethnicity, socioeconomic and family key worker status end of article. ethnicity, key worker status and socioeconomics with incidence and severity of Paediatric Inflammatory impact the severity and risk of COVID-19 Multisystem Syndrome Temporally associated with SARS- Correspondence to disease. Paediatric Inflammatory Multisystem CoV-2 (PIMS- TS). Dr Jonathan Broad, Paediatric Syndrome, Temporally associated with SARS- infectious disease, Evelina Setting Evelina London Children’s Hospital (ELCH), the CoV-2 (PIMS- TS) is a novel disease associated London Children’s Healthcare, tertiary paediatric hospital for the South Thames Retrieval London SE1 7EH, UK; with COVID-19 disease, and case series suggest Service (STRS) region.
    [Show full text]
  • Gene Therapy Is
    Gene therapy is now Annual report and accounts 2017 Oxford BioMedica in brief Oxford BioMedica is a pioneer of gene and cell therapy with a leading position in lentiviral vector and cell therapy research, development and bioprocessing. Gene and cell therapy is the treatment of disease by the delivery of therapeutic DNA into a patient’s cells. This can be achieved either in vivo (referred to as gene therapy) or ex vivo (referred to as cell therapy), the latter being where the patient's cells are genetically modified outside the body before being re-infused. Oxford BioMedica is focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 300 people. Introducing Oxford BioMedica 1 At the front and centre 3 Multi-billion $ market sector 3 Targeting unmet needs 4 Enabling new treatments 4 Sharing
    [Show full text]
  • Autumn 2019 Education Is Liberation
    Bradfordian Issue 353 The | Autumn 2019 Education is liberation. Dr Simon Hinchlife Headmaster Extract from Speech Day 2019 For the full speech please turn to page 07 School Notes Arts and Performance Communities, Trips Events and Sporting Achievements JUNIOR, SENIOR AND SENIOR AND SIXTH FORM Societies and Activities SENIOR AND SIXTH FORM Visiting Speakers SENIOR AND SIXTH FORM SIXTH FORM 64–71 SENIOR AND SIXTH FORM 88–95 SENIOR AND SIXTH FORM 104–109 Contents 06–29 74–85 98–101 Clay extravaganza Junior Classics trip to the The Race Ace! Bay of Naples From the Headmaster Youth Speaks team Best ever GCSE results Dr Zoe Williams inspired Swimming championships Classics Trip to London students to reach for their Speech Day 2019 – Computer Science Outstanding A Level success Running club aspirational goals Headmaster’s Speech and Cybersecurity European Day of Languages First World War centenary: Prestigious training Mental health is about more Staf Leavers Art Society observations marking 100 years Battlefields of the programme for our Contents than just talking First World War Hockey Coach University Degree Course Exhibition follows in Hockney’s Year 9 cross-curricular First TV’s Dan Snow talks history Admissions and Vocations footsteps World War Day Vecht rowing trip Team GB’s Emile makes an 2019 Open Science Lecture Series: exciting return to Bradford Pupils’ art showcase raises over Internationally acclaimed Vecht racing in the Netherlands From young to old, from rare Grammar Examination Results 2019 £1,000 for NSPCC cricketer inspires
    [Show full text]